weekly_roundup

BioTechSign Daily Catalyst Roundup - October 28, 2026

Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisOctober 28, 2026

Daily Biotech Catalyst Digest: October 28, 2026

ITCI leads the current BioTechSign screen at 100.0/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
ITCIIntra-Cellular Therapies100.0Aclinical activity 100%
DCPHDeciphera Pharmaceuticals100.0Aclinical activity 100%
BGNEBeiGene Ltd100.0Apublication signal 100%, clinical activity 100%
AKBAAkebia Therapeutics87.2Aclinical activity 92%, short interest 50%
RGNXREGENXBIO Inc86.4Apublication signal 100%, clinical activity 100%, short interest 70%
SRPTSarepta Therapeutics85.9Aclinical activity 100%, short interest 70%, dilution risk 48%

Recent Grade-Change Queue

  • BBIO (BridgeBio Pharma) currently grades C with a 50.4/100 catalyst score. Main inputs: PDUFA timing 90%, short interest 50%, dilution risk 35%.
  • TVRD (Tvardi Therapeutics, Inc.) currently grades D with a 36.1/100 catalyst score. Main inputs: dilution risk 86%, short interest 30%, clinical activity 21%.
  • PRAX (Praxis Precision Medicine) currently grades D with a 42.0/100 catalyst score. Main inputs: PDUFA timing 75%, short interest 50%, dilution risk 26%.
  • UCBNV (UCB SA) currently grades F with a 13.7/100 catalyst score. Main inputs: publication signal 75%, clinical activity 12%.
  • SNY (Sanofi SA) currently grades D with a 46.9/100 catalyst score. Main inputs: clinical activity 62%, dilution risk 12%, short interest 10%.
  • RCUS (Arcus Biosciences) currently grades C with a 61.6/100 catalyst score. Main inputs: clinical activity 67%, dilution risk 50%, short interest 50%.
  • PBYI (Puma Biotechnology Inc) currently grades C with a 54.0/100 catalyst score. Main inputs: publication signal 100%, clinical activity 62%, short interest 50%.
  • OPK (OPKO Health, Inc.) currently grades F with a 21.7/100 catalyst score. Main inputs: short interest 50%, dilution risk 27%, clinical activity 17%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.